1. Home
  2. NTRA

as of 11-13-2026 3:36pm EST

$320.34
$1.65
-0.51%
Stocks Health Care Medical Specialities Nasdaq

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Founded: 2003 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 56.7B IPO Year: 2015
Target Price: $410.02 AVG Volume (30 days): 1.9M
Analyst Decision: Strong Buy Number of Analysts: 22
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.48 EPS Growth: 0.65
52 Week Low/High: $181.00 - $437.41 Next Earning Date: 11-05-2026
Revenue: $210,939,000 Revenue Growth: -2.83%
Revenue Growth (this year): 30.65% Revenue Growth (next year): 21.31%
P/E Ratio: -217.55 Index: N/A
Free Cash Flow: 109.1M FCF Growth: -50.53%

Stock Insider Trading Activity of Natera Inc. (NTRA)

Brophy Michael Burkes

CHIEF FINANCIAL OFFICER

Sell
NTRA Nov 3, 2026

Avg Cost/Share

$391.49

Shares

470

Total Value

$184,000.30

Owned After

45,779

SEC Form 4

Moshkevich Solomon

PRESIDENT, CLINICALDIAGNOSTICS

Sell
NTRA Nov 2, 2026

Avg Cost/Share

$408.31

Shares

3,419

Total Value

$1,400,994.29

Owned After

102,403

RABINOWITZ DANIEL

SEC. AND CHIEF LEGAL OFFICER

Sell
NTRA Nov 2, 2026

Avg Cost/Share

$394.25

Shares

341

Total Value

$136,415.66

Owned After

167,880

Fesko John

PRESIDENT, CHIEF BUS. OFFICER

Sell
NTRA Nov 2, 2026

Avg Cost/Share

$394.25

Shares

302

Total Value

$120,804.19

Owned After

195,276

Brophy Michael Burkes

CHIEF FINANCIAL OFFICER

Sell
NTRA Nov 2, 2026

Avg Cost/Share

$394.16

Shares

325

Total Value

$129,997.50

Owned After

45,779

Rabinowitz Matthew

EXECUTIVE CHAIRMAN

Sell
NTRA Nov 2, 2026

Avg Cost/Share

$394.25

Shares

748

Total Value

$299,214.46

Owned After

2,117,659

Sheena Jonathan

Director, Other

Sell
NTRA Nov 2, 2026

Avg Cost/Share

$394.25

Shares

112

Total Value

$44,796.67

Owned After

214,745

Chapman Steven Leonard

CEO AND PRESIDENT

Sell
NTRA Nov 2, 2026

Avg Cost/Share

$401.28

Shares

3,801

Total Value

$1,565,239.04

Owned After

87,431

SEC Form 4

Form 1 Form 2
Moshkevich Solomon

PRESIDENT, CLINICALDIAGNOSTICS

Sell
NTRA Oct 28, 2026

Avg Cost/Share

$426.34

Shares

1,162

Total Value

$495,407.54

Owned After

102,403

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 5, 2026 · 100% conf.

AI Prediction SELL

1D

-5.48%

$369.60

Act: -12.34%

5D

-7.76%

$360.69

20D

-5.64%

$368.97

Price: $391.03 Prob +5D: 0% AUC: 1.000
0001604821-26-000032

EX-99.1

2 ntra-20260930xex991.htm

EX-99.1

Document

Exhibit 99.1

Natera Reports Third Quarter 2026 Financial Results

AUSTIN, Texas, November 5, 2026 /BUSINESS WIRE/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026.

Recent Financial Highlights

•Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.

•Generated a gross margin1 of 64.7% in the third quarter of 2026, compared to a gross margin1 of 64.9% in the third quarter of 2025. Excluding revenue true-ups, third quarter non-GAAP gross margin2 increased by 137 basis points over the second quarter of 2026.

•Processed approximately 1,093,100 tests in the third quarter of 2026, compared to approximately 893,600 tests in the third quarter of 2025, an increase of 22.3%.

•Processed approximately 339,500 oncology tests in the third quarter of 2026, compared to approximately 211,000 in the third quarter of 2025, an increase of 60.9%. Clinical molecular residual disease (MRD) oncology units grew 32,700 units over the second quarter of 2026.

•Increased cash by approximately $5.7 million3 as of September 30, 2026 compared to June 30, 2026.

•Raised 2026 annual revenue guidance by $140 million at the midpoint, from $2.850 billion - $2.910 billion to $3.005 billion - $3.035 billion.

Third Quarter Ended September 30, 2026 Financial Results

Total revenues were $794.0 million in the third quarter of 2026 compared to $592.2 million in the third quarter of 2025, an increase of 34.1%. The increase in revenues was driven by an increase in volume and average selling price improvements.

Natera processed approximately 1,093,100 tests in the third quarter of 2026, including approximately 1,080,300 tests accessioned in its laboratory, compared to approximately 893,600 tests processed, including approximately 879,700 tests accessioned in its laboratory, in the third quarter of 2025.

In the third quarter of 2026, Natera recognized revenue on approximately 1,024,800 tests for which results were reported to customers in the period (tests reported), including approximately 1,012,100 tests reported from its laboratory, compared to approximately 832,900 tests reported, including approximately 819,900 tests reported from its laboratory, in the third quarter of 2025, an increase of 23.0% from the prior period.

Gross profit1 for the three months ended September 30, 2026 and 2025 was $513.5 million and $384.4 million, respectively, representing a gross margin1 of 64.7% and 64.9%, respectively. This was primarily as a result of higher revenues and continued progress in reducing cost of revenues, offset by a smaller benefit from changes in estimates. Changes in estimates for the three months ended September 30, 2026 and 2025 increased revenue and, as a result, increased gross margin1 by 1.5% and 3.6%, respectively, and increased gross profit1 by $32.3 million and $55.1 million, respectively. The decrease in the change in estimate reflects the continued accumulation of historical collection experience, which has resulted in our estimates of variable consideration at the time of revenue recognition more closely approximating subsequent cash collections.

Gross margin1 for the three months ended June 30, 2026 was 64.5%. Excluding the change in estimates in revenue accruals of approximately $32.3 million and $52.3 million during the three months ended September 30, 2026 and June 30, 2026, respectively, Natera's non-GAAP gross margin2 increased by approximately 1.4% sequentially.

Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the third quarter of 2026 was $576.1 million, compared to $482.0 million in the same period of the prior year, an increase of 19.5%. The increase was primarily driven by headcount growth to support new product offerings as well as increases in clinical trial expenses. Amortization of acquired intangible assets for the third quarter of 2026 was $5.7 million. No such amortization occurred in the third quarter of 2025.

Loss from operations for the third quarter of 2026 was $68.3 million compared to $97.6 million for the same period of the prior year.

Natera’s net loss for the third quarter of 2026 was $59.9 million, or ($0.42) per diluted share, compared to a net loss of $87.5 million, or ($0.64) per diluted share, in the third quarter of 2025. Weighted average shares outstanding were 144.1 million in the third quarter of 2026 compared to 137.2 million for the same period in the prior year.

At September 30, 2026, Natera held approximately $1,097.2 million in cash, cash equivalents, and restricted cash, compared to $1,076.1 million as of December 31, 2025. As of September 30, 2026, Natera had a total outstanding debt balance of $80.3 million, including accrued interest un

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 6, 2026 · 100% conf.

AI Prediction SELL

1D

-5.51%

$250.76

Act: +21.37%

5D

-7.76%

$244.78

20D

-5.64%

$250.40

Price: $265.38 Prob +5D: 0% AUC: 1.000
0001604821-26-000015

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.ed18d017.1786388355.cfebfb1a

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

-4.68%

$209.53

Act: -11.32%

5D

-7.38%

$203.59

Act: -10.42%

20D

-6.16%

$206.28

Act: -2.05%

Price: $219.82 Prob +5D: 0% AUC: 1.000
0001628280-26-032101

EX-99.1

2 ntra-20260331xex991.htm

EX-99.1

Document

Exhibit 99.1

Natera Reports First Quarter 2026 Financial Results

AUSTIN, Texas, May 7, 2026 /BUSINESS WIRE/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026.

Recent Financial Highlights

•Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%.

•Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter of 2025.

•Processed approximately 1,013,600 tests in the first quarter of 2026, compared to approximately 855,100 tests in the first quarter of 2025, an increase of 18.5%. Women’s Health generated the second highest quarterly unit growth since 2019 and Oncology delivered another record quarter for volume growth.

•Processed approximately 258,900 oncology tests in the first quarter of 2026, compared to approximately 167,700 in the first quarter of 2025, an increase of 54.4%.

•Achieved positive cash inflow of approximately $11.8 million2 in the first quarter of 2026.

•Raising 2026 annual revenue guidance by $120 million at the midpoint, from $2.62 billion - $2.70 billion to $2.74 billion - $2.82 billion.

“We had an outstanding first quarter, reaching over one million units processed in a single quarter for the first time and delivering strong growth across all areas,” said Steve Chapman, chief executive officer of Natera. “We are seeing the impact of strong 2025 data readouts and innovation translating into increased adoption, particularly for Signatera™ and Fetal Focus™, reinforcing our confidence in the long-term opportunity to transform patient care.”

First Quarter Ended March 31, 2026 Financial Results

Total revenues were $696.6 million in the first quarter of 2026 compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. The increase in revenues was driven by an increase in volume and average selling price improvements.

Natera processed approximately 1,013,600 tests in the first quarter of 2026, including approximately 999,200 tests accessioned in its laboratory, compared to approximately 855,100 tests processed, including approximately 840,800 tests accessioned in its laboratory, in the first quarter of 2025.

In the first quarter of 2026, Natera recognized revenue on approximately 931,600 tests for which results were reported to customers in the period (tests reported), including approximately 918,100 tests reported from its laboratory, compared to approximately 804,800 tests reported, including approximately 791,400 tests reported from its laboratory, in the first quarter of 2025, an increase of 15.8% from the prior period.

Gross profit2 for the three months ended March 31, 2026 and 2025 was $450.8 million and $316.8 million, respectively, representing a gross margin1 of 64.7% and 63.1%, respectively. Natera had higher gross margin1 in the first quarter of 2026 primarily as a result of higher revenues and continued progress in reducing cost of revenues associated with tests processed. Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the first quarter of 2026 was $538.6 million, compared to $395.9 million in the same period of the prior year, an increase of 36.0%. The increase was primarily driven by headcount growth to support new product offerings as well as increases in clinical trial expenses. Amortization of acquired intangible assets for the first quarter of 2026 was $5.7 million. No such amortization occurred in the first quarter of 2025.

Loss from operations for the first quarter of 2026 was $93.5 million compared to $79.2 million for the same period of the prior year.

Natera’s net loss for the first quarter of 2026 was $85.1 million, or ($0.60) per diluted share, compared to a net loss of $66.9 million, or ($0.50) per diluted share, in 2025. Weighted average shares outstanding were 141.5 million in the first quarter of 2026 compared to 134.8 million for the same period in the prior year.

At March 31, 2026, Natera held approximately $1,087.9 million in cash, cash equivalents, and restricted cash, compared to $1,076.1 million as of December 31, 2025. As of March 31, 2026, Natera had a total outstanding debt balance of $80.3 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.

Financial Outlook

Natera anticipates 2026 total revenue of $2.74 billion to $2.82 billion; 2026 gross margin1 to be approximately 64% to 66%; selling, general and administrative costs to be approximately $1.125 billion to $1.225 billion; research and development costs to be $800 million to $900 million; and net cash inflow to be positive3.

Test Volume Summary

Unit

QTD 2026

QTD 2025

Definition

Tests processed 1,013

Share on Social Networks: